EyePoint Completes Phase 3 Enrollment For DME Drug DURAVYU
EyePoint Inc. has completed enrollment for its pivotal DURAVYU trials for diabetic macular edema, achieved in just five months with 480 patients. Topline data is anticipated in 4Q 2027, followed by FDA and EMA review.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day